Unspecified

Extract from the above information

Entecavir is a guanine nucleoside analog that inhibits hepatitis B virus (HBV) polymerase. It can be converted into an active triphosphate through phosphorylation, and the half-life of the triphosphate in cells is 15 hours. Entecavir triphosphate can inhibit all three activities of viral polymerase (reverse transcriptase): (1) the initiation of HBV polymerase; (2) the formation of the reverse transcriptase negative strand of pregenomic mRNA; (3) the synthesis of the HBV DNA positive strand.

This product has a broad-spectrum antibacterial effect and strong antibacterial effect. It has strong antibacterial activity against most Enterobacteriaceae, such as Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, and Gram-negative bacteria such as Haemophilus influenzae, Legionella pneumophila, and Neisseria gonorrhoeae. It also has antibacterial effects on Gram-positive bacteria such as Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes, and Mycoplasma pneumoniae and Chlamydia pneumoniae, but has poor effects on anaerobic bacteria and enterococci. This product is the levorotatory form of ofloxacin, and its in vitro antibacterial activity is about twice that of ofloxacin. Its mechanism of action is to inhibit the activity of bacterial DNA gyrase, prevent the synthesis and replication of bacterial DNA, and cause bacterial death.

It has strong anti-inflammatory, liver cell membrane protection and liver function improvement effects. It can reduce the increase of serum alanine aminotransferase and aspartate aminotransferase caused by carbon tetrachloride, thioacetamide and D-aminogalactic acid, reduce the morphological damage of D-aminogalactic acid to the liver and improve the chronic damage of immune factors to the liver morphology.